THE INSULIN RECEPTOR IN ASTROCYTES IS INVOLVED IN THE ENTRANCE OF CIRCULATING INSULIN INTO THE BRAIN

Ana M. Fernandez[1,2], Jose Carlos Davila[2,3], Cristina Garcia-Caceres[4], Matthias Tschöp[4], Antonia Gutierrez[2,3], and Ignacio Torres Aleman[1,2]

[1]Cajal Institute, Madrid, Spain; [2]Ciberned, Spain; [3] Dept. Cell Biology, Genetics and Physiology, Instituto de Investigacion Biomedica de Malaga-IBIMA, Faculty of Sciences, University of Malaga, Spain; and [4]Institute for Diabetes and Obesity, Munich, Germany.

Correspondence to: I Torres Aleman (torres@cajal.csic.es)

Abstract

Circulating insulin enters into the brain through mechanisms that are not yet entirely understood. We now report that mice lacking insulin receptors (IR) in astrocytes show reduced uptake of circulating insulin and blunted brain responses to this circulating hormone, suggesting that astrocytes form part of the cellular pathway in the entrance of circulating insulin into the brain. Since we previously showed that ablation of IR in astrocytes decreases brain glucose uptake, we conclude that astrocytic IRs regulate uptake of circulating glucose and insulin.

Introduction

The origin of insulin in the brain has been a matter of debate until relatively recently (Gray et al., 2014). Early observations documented the presence of insulin in the cerebrospinal fluid (CSF) and the brain (Margolis and Altszuler, 1967; Pansky and Hatfield, 1978). Because expression of insulin by brain cells was firmly established only recently (Kuwabara, 2011), for many years, insulin actions in the brain were assumed to arise from pancreatic insulin (Schwartz and Porte, 2005) that has to cross the blood-brain-barriers (BBBs). Indeed, there are insulin receptors (IR) in the cells forming the BBBs; that is, epithelial cells at the choroid plexus (Baskin et al., 1986), brain capillary endothelial cells (Frank et al., 1986) that transcytose insulin (King and Johnson, 1985), and astrocytes (Baron-Van et al., 1991). Accordingly, previous observations indicated that insulin from the circulation enters the brain through a transport mechanism involving its receptor in brain endothelial cells forming the BBB (Gray et al., 2017), although more recent observations indicate that the process may be IR independent (Hersom et al., 2018; Rhea et al., 2018).

Astrocytes seal brain endothelial cells of brain capillaries by wrapping them with their end-feet (Mathiisen et al., 2010). In this way, astrocytes constitute an additional cell layer of the BBB (Zlokovic, 2008). Once insulin has being transported across endothelial cells (King and Johnson, 1985), it may be taken up by astrocytes either to be further transported into the brain parenchyma through transcytosis (Simionescu et al., 2002), to modulate the activity of these glial cells (Cai et al., 2018), or both. To help clarify the route of entrance of circulating insulin into the brain, we analyzed its brain uptake in mice lacking IR in astrocytes. Ablation of IR in astrocytes blocked the entrance of circulating insulin into the brain, suggesting that astrocytes form part of the intracellular pathway of passage of this hormone into the brain.

Results

IR are present in astroglial end-feet

We first determined whether IR are present in astrocytic end-feet ensheathing endothelial cells of the BBB, as its presence in this compartment will allow circulating insulin to readily access astrocytes. Using combined IR immunogold labeling and electron microscopy we localized these receptors in astrocytic end-feet (Figure 1A,B). This anatomical location, in close proximity to endothelial cells, together with the expression of IR in the latter type of cells (Figure 1B), or as an yet uncharacterized

transporter (Rhea et al., 2018), would allow the passage of circulating insulin into astrocytes by transcytosis through endothelial cells (Gray et al., 2017).

Astrocytic IR are required for brain IR activation by circulating insulin

As already documented (Sartorius et al., 2015), systemic administration of insulin results in robust activation of brain IR (Figure 2A). However, GFAP IR KO mice show attenuated responses to peripheral insulin injection, as determined by reduced phosphorylation of brain (Figure 2B), but not muscle IR (Figure 2C). The reduction in brain IR phosphorylation was not due to lower brain IR levels in mutant mice as a result of the ablation of astrocytic IR since receptor activation was normalized by its relative levels (similar between tamoxifen-treated and non-treated mice; see lower blot in Figure 2B). Furthermore, GFAP IR KO mice show normal brain insulin-like growth factor I (IGF-I) receptor phosphorylation in response to systemic injection of this close relative of insulin (Suppl Fig 1A), indicating specific loss of sensitivity to systemic insulin.

Astrocytic IR are involved in brain uptake of circulating insulin

To analyze the pathways involved in the passage of circulating insulin into the brain with greater detail, we injected mice with digoxigenin-labelled insulin (Dig-Ins) in the carotid artery and examined its route of entrance by immunolabelling. In control GFAP IR KO mice (not injected with tamoxifen) neuronal digoxigenin staining was readily seen (Figure 3A, panels b-c, and B). However, in tamoxifen-treated GFAP IR KO mice, neuronal staining was lost (Figure 3C, panels b-c, and D). In addition, a strong Dig-Ins staining in vessels was seen in these animals (Figure 3C, panel a, and Suppl Fig 1B), suggesting that it is retained inside the endothelium without crossing into the brain parenchyma.

Discussion

The first cell layer separating the brain parenchyma from the circulation through the BBB is formed by brain endothelial cells. Whether insulin receptors in these cells are involved in the transport of circulating insulin into the brain, is controversial (King and Johnson, 1985; Gray et al., 2017; Hersom et al., 2018; Rhea et al., 2018). The second cell layer of the BBB is formed by astrocytic end-feet. The present observations indicate that insulin receptors in astrocytes are involved in the entrance of circulating insulin into the brain. Once insulin is transcytosed by brain endothelial cells through a regulated process, involving or not its receptor (Banks, 2004; Gray et al., 2017), it is then taken up by astrocytes in a receptor-mediated process to deliver it to neighboring neurons. Hence,

circulating insulin access astrocytes not only to modulate their function (Garcia-Caceres et al., 2016; Cai et al., 2018), but also as a gate of entrance to neurons, as blockade of this pathway results in blockade of neuronal uptake.

Although circulating insulin plays many important roles in the brain, the key question of how it reaches its numerous brain targets remained, until now, poorly characterized. Indeed, it might be of great relevance to know the route of entrance of serum insulin into the brain as in diabetes and several neurodegenerative diseases, brain insulin resistance is a likely pathogenic component. Knowing whether reduced entrance of insulin into the brain and/or loss of sensitivity of brain cells underlie reduced brain insulin function in these pathologies will greatly assist new therapeutic options. In conjunction with recent observations that mice without IR in astrocytes show a depressive phenotype (Cai et al., 2018), the present results pose astrocytic IRs as important targets for future therapies.

Materials and Methods

Animals: Wild type 6 month-old male mice (C57BL6/J) were used in EM experiments. Also, mice with insulin receptors ablated in astrocytes (GFAP IR KO mice) under regulation of tamoxifen were generated as described in detail before (Garcia-Caceres et al., 2016), by crossing hGFAP-CreER^{T2} on a C57 BL/6J background (FM Vaccarino, Yale Univ) with IR$^{f/f}$ mice having the IR gene flanked by loxP sites (R Kahn, Joslin Diabetes Center). Intraperitoneal injection of tamoxifen for 5 consecutive days (75 mg/kg) to adult GFAP IR KO mice (4-5 weeks old) eliminated IR specifically in astrocytes, as reported (Garcia-Caceres et al., 2016), and resulted in significantly decreased IR content in brain (Suppl Fig 1C). Controls received vehicle injections (corn oil). GFAP IR KO mice were genotyped using PCR protocols already detailed (Garcia-Caceres et al., 2016). Mice had access to food and water *ad libitum* and were kept under light/dark conditions. Animal procedures followed European (86/609/EEC & 2003/65/EC, European Council Directives) guidelines and studies were approved by the respective local Bioethics Committees (CAM PROEX 01/14).

Reagents: The following reagents were used: tamoxifen (Sigma, Darmstadt, Germany), Insulin (Sigma), IGF-1 (PreproTech, Rocky Hill, NJ, USA), and tomato lectin-FITC (Sigma),. Antibodies used were: Phosphotyrosine (clone PY20, BD Transduction laboratories, San Jose, CA, USA), GFAP (Dako, Glostrup, DK), NeuN (Millipore, Darmstad, Germany), Digoxigenin (Roche Diagnostics, Mannheim, Germany), Insulin

receptor ß (Santa Cruz Biotechnology, Dallas, TX, USA), IGF-1 receptor ß (Cell Signaling Technology, Danvers, MA, USA) and ß-actin (Sigma,).

Digoxigenin-labeled insulin: 100 µl of 1 mg/ml recombinant human insulin (Sigma) was mixed with 1 ml of PBS pH 8.5. Digoxigenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (NHS-Dig; Roche Diagnostics) dissolved in dimethyl sulfoxide (DMSO) was added to the insulin solution at a molar ratio of 1:5. After incubation at room temperature for 2 h, non-reacted NHS-Dig was removed by a Sephadex G-25 column (GE Healthcare, Chicago, IL, USA). Digoxigenin-labeled insulin (Dig-insulin) was stored at -20°C until use.

Insulin administration: Mice were anesthetized with isofluorane (with oxygen flux at 0.8–1 l/min). The common carotid artery was exposed and the external carotid ligated. A guide cannula was inserted in the common carotid artery and 100µl Dig-insulin was injected using a Hamilton syringe coupled to a nanoinjector. After 1 hour, mice were perfused with saline and 4% paraformaldehyde. Brains were removed and processed for immunohistochemistry. For IR phosphorylation experiments, mice were injected with 5 IU insulin intraperitoneally. After 1h, mice were perfused with saline and brain and skeletal muscle isolated, frozen until assayed by IR immunoprecipitation and Western blotted with anti-pTyr.

Immunofluorescence: Immunolabeling was performed as described (Fernandez et al., 2012). Mice were deeply anesthetized with pentobarbital (50 mg/kg), and perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB). Brains were dissected, and coronal 50-µm-thick brain sections were cut in a vibratome and collected in PB. Sections were incubated to block non-specific antibody binding, followed by incubation overnight at 4°C with the primary antibodies in PB - 1% bovine serum albumin - 1% Triton X-100 (PBT). After several washes in PBT, sections were incubated with the corresponding Alexa-coupled secondary antibody (1:1000, Molecular Probes, ThermoFisher Scientific) diluted in PBT. Again, three 5-minute washes in PBT were required. Slices were rinsed several times in PB, mounted with gerbatol mounting medium, and allowed to dry. For endothelial cell staining, sections were incubated with Tomato lectin-FITC overnight at 4ºC followed by several washes in PBT. Omission of primary antibodies was used as control. Confocal analysis was performed in a Leica microscope (Wetzlar, Germany).

Immunoprecipitation and Western blotting: Immunoassays were performed as described (Fernandez et al., 2007). Brain tissue was homogenized in ice-cold buffer

with 10mM Tris HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 0.5% NP40, 1mM sodium orthovanadate, and a protease inhibitor cocktail (Sigma) plus 2mM PMSF, using 1 ml of buffer per mg of tissue. Insoluble material was removed by centrifugation, and supernatants were incubated overnight at 4 ºC with the antibodies. Immunocomplexes were collected with Protein A/G agarose (Santa Cruz Biotechnology) for 1 h at 4 °C and washed 3X in homogenization buffer before separation by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After blocking for 1 h with 5% BSA in TTBS (20 mM Tris-HCl, pH 7.4, 150 M NaCl, 0.1% Tween 20), membranes were incubated overnight at 4 ºC with the different antibodies in TTBS, washed, incubated with secondary antibodies and develop using the Odissey procedure (Li-Cor Biosciences, Lincoln, NE, USA).

Immunoelectron microscopy: Immunogold procedure was performed as previously described (Gomez-Arboledas et al., 2018)**.** After deep anesthesia with sodium pentobarbital (60 mg/kg), 6 month-old male mice (C57BL6/J) were perfused transcardially with 0.1 M phosphate-buffered saline (PBS), pH 7.4 followed by fixative solution containing 4% paraformaldehyde, 75 mM lysine and10 mM sodium metaperiodate in 0.1 M PB, pH 7.4. Brains were removed, post-fixed overnight in the same fixative solution at 4°C, coronally sectioned at 50 μm thicknesses on a vibratome (Leica VT1000S), and serially collected in wells containing cold PB and 0.02% sodium azide. For IGF-1R or IR immunogold labelling, sections containing the somatosensory cortex were used. Sections were first washed with PBS and incubated in a 50 mM glycine solution 5 minutes to increase antibody binding efficiency. Following a standard immunohistochemical protocol, tissue was first free-floating incubated in a rabbit polyclonal anti-IGF-IRα antibody or a anti-IR antibody in a PBS 0.1M/1% BSA solution for 48 hours at 22ºC. Then, sections were washed in PBS, and incubated with 1.4 nm gold-conjugated goat anti-rabbit IgG (1:100; Nanoprobes) overnight at 22ºC. After post-fixing with 2% glutaraldehyde and washing with 50 mM sodium citrate, labelling was enhanced with the HQ Silver^{TM} Kit (Nanoprobes), and gold toned. Finally, immunogold labelled sections were fixed in 1% osmium tetroxide, block stained with uranyl acetate, dehydrated in acetone, and flat embedded in Araldite 502 (EMS, USA). Selected areas were cut in ultrathin sections (70-80 nm) and examined and photographed with a JEOL JEM1400 electron microscope. As a control for the immunogold technique, sections were processed as above but omitting the primary antibody. No specific labelling was observed in these control sections.

Statistics: Statistical analysis was performed using GraphPad Prism 5.0 (La Jolla, CA, USA). To compare differences between two groups, Student's t-test (Gaussian distribution of data) or Mann–Whitney test (non-Gaussian distribution of data) were used. To compare multiple variables, two-way ANOVA was used, followed by a Bonferroni post hoc test to compare replicate means. Statistical differences were considered when $p < 0.05$. Results are presented as mean ± SEM of five to eight mice per group. (*$p< 0.05$, **$p< 0.01$, ***$p< 0.001$).

Acknowledgments

We are thankful to M. Garcia for technical support. This work was funded by a grant from Ciberned, an Inter-CIBER project (PIE14/00061), and SAF2016-76462-C2-1-P (MINECO) to ITA, and grant PI18/01557 (to AG) from Instituto de Salud Carlos III (ISCiii) of Spain (co-financed by FEDER funds from European Union).

LEGENDS TO FIGURES

Figure 1: IR is expressed by astrocyte end-feet. A, Electron microscopy photograph using immuno-gold labeling for IR illustrating the presence of immunoeractive IR deposits in astroglial end-feet surrounding brain capillaries and in endothelial cells. **B,** A1 and A2 squares from A, are shown at greater magnification. Note the presence of IR gold particles in endothelial cells (red arrows) and astrocytic end-feet (black arrows). Bar in A is 2 µm, and in B, 0.5 µm.

Figure 2: Systemic injection of insulin stimulates IR phosphorylation in cortex. A, Intraperitoneal injection of insulin (5 U/ml) results in stimulation of IR in the mouse somatosensory cortex as compared to control mice (injected with the same amount of saline). **B,** Ablation of IR in GFAP IR KO astrocytes after tamoxifen administration results in markedly reduced activation of cortical IR after systemic insulin in comparison to vehicle (corn oil) injected mice. **C,** In these animals, activation of muscle IR was intact, as compared to oil-injected GFAP IR KO mice. Activation of IR is shown as amount of Tyrosine phosphorylated receptor (pTyr) normalized by total levels of immunoprecipitated IR. Representative blots are shown. Quantification of changes is shown in histograms (n=8 for each group; *$p<0.05$ vs respective control mice).

Figure 3: Insulin receptors in astrocytes are required for neurons to capture circulating insulin. A, Intra-carotid injection of digoxigenin-labeled insulin (Dig-insulin) results in its neuronal accumulation only when astrocytes express IR (no tamoxifen). Panel a shows astrocyte end-feet ($GFAP^+$ in green) ensheathing brain capillaries in control (-tamoxifen) mice receiving Dig-insulin injections. No Dig staining is seen. In contrast, Dig staining is seen in cell of panel b (white dotted square) with neuronal morphology (red), that are magnified in panel c (white asterisks). **B**, Accumulation of labeled insulin is readily seen in hippocampal neurons ($NeuN^+$ cells) of control mice (no tamoxifen). **C,** GFAP IR KO mice (treated with tamoxifen) do not show Dig staining in neurons after intracarotid injection of Dig-insulin. In panel a, vessels surrounded by $GFAP^+$ astroglial end-feet show abundant digoxigenin staining, suggesting lower transfer of Dig-insulin into the brain. In panels b and c (higher magnification of dotted white square in b) neuronal-like shapes with Dig staining are

absent. Note the pronounced GFAP reactivity of astrocytes as compared to panel c in A. **D,** GFAP IR KO (+tamoxifen) do not show NeuN$^+$ (green) cells co-labelled with Dig in the hippocampal granular cell layer. Green: GFAP$^+$ or NeuN$^+$ cells; Red: Digoxigenin$^+$ cells.

Supplementary Figure 1: **A,** Systemic injection of IGF-I to GFAP IR KO mice stimulates phosphorylation of its receptors in cortex. **B,** Digoxigenin staining in brain vessels (tomato lectin$^+$ cells) of control (no tamoxifen) and GFAP IR KO mice (+ tamoxifen). **C,** GFAP IR KO mice show reduced IR levels in brain, as compared to controls (treated with tamoxifen vehicle; **$p<0.01$ vs control).

References

Banks WA (2004) The source of cerebral insulin. Eur J Pharmacol 490:5-12.

Baron-Van EA, Olichon-Berthe C, Kowalski A, Visciano G, Van OE (1991) Expression of IGF-I and insulin receptor genes in the rat central nervous system: a developmental, regional, and cellular analysis. J Neurosci Res 28:244-253.

Baskin DG, Brewitt B, Davidson DA, Corp E, Paquette T, Figlewicz DP, Lewellen TK, Graham MK, Woods SG, Dorsa DM (1986) Quantitative autoradiographic evidence for insulin receptors in the choroid plexus of the rat brain. Diabetes 35:246-249.

Cai W, Xue C, Sakaguchi M, Konishi M, Shirazian A, Ferris HA, Li ME, Yu R, Kleinridders A, Pothos EN, Kahn CR (2018) Insulin regulates astrocyte gliotransmission and modulates behavior. The Journal of Clinical Investigation 128:2914-2926.

Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I (2007) Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci 27:8745-8756.

Fernandez AM, Jimenez S, Mecha M, Davila D, Guaza C, Vitorica J, Torres-Aleman I (2012) Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. Mol Psychiatry 17:705-718.

Frank HJ, Pardridge WM, Morris WL, Rosenfeld RG, Choi TB (1986) Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes 35:654-661.

Garcia-Caceres C et al. (2016) Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell 166:867-880.

Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, Navarro V, Nunez-Diaz C, Sanchez-Varo R, Sanchez-Mico MV, Trujillo-Estrada L, Fernandez-Valenzuela JJ, Vizuete M, Comella JX, Galea E, Vitorica J, Gutierrez A (2018) Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. Glia 66:637-653.

Gray SM, Meijer RI, Barrett EJ (2014) Insulin regulates brain function, but how does it get there?. Diabetes 63:3992-3997.

Gray SM, Aylor KW, Barrett EJ (2017) Unravelling the regulation of insulin transport across the brain endothelial cell. Diabetologia 60:1512-1521.

Hersom M, Helms HC, Schmalz C, Pedersen TA, Buckley ST, Brodin B (2018) The insulin receptor is expressed and functional in cultured blood-brain barrier endothelial cells, but does not mediate insulin entry from blood-to-brain. Am J Physiol Endocrinol Metab 315:531-542.

King GL, Johnson SM (1985) Receptor-mediated transport of insulin across endothelial cells. Science 227:1583-1586.

Kuwabara TK (2011) Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Molecular Medicine 3:742-754.

Margolis RU, Altszuler N (1967) Insulin in the cerebrospinal fluid. Nature 215:1375-1376.

Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP (2010) The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58:1094-1103.

Pansky B, Hatfield JS (1978) Cerebral localization of insulin by immunofluorescence. Am J Anat 153:459-467.

Rhea EM, Rask-Madsen C, Banks WA (2018) Insulin transport across the blood–brain barrier can occur independently of the insulin receptor. The Journal of Physiology 596:4753-4765.

Sartorius T, Peter A, Heni M, Maetzler W, Fritsche A, Haring HU, Hennige AM (2015) The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?. PLoS ONE 10:e0126804.

Schwartz MW, Porte D (2005) Diabetes, obesity, and the brain. Science 307:375-379.

Simionescu M, Gafencu A, Antohe F (2002) Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey. Microsc Res Tech 57:269-288.

Zlokovic BV (2008) The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron 57:178-201.

A



B



Figure 1

A


saline
Insulin
PTyr
IR
IP: IR


pTyr IR/IR
(Fold change)
1
0
*
Saline
Insulin

B


Insulin
Tamoxifen
-
+
-
+
pTyr
IR
IP: IR


pTyr IR/IR
(Fold change)
1,2
1
0,8
0,6
0,4
0,2
0
*
Vehicle
Tamoxifen

C


Insulin
Tamoxifen
-
+
pTyr
IR
IP: IR

Figure 2


A
- Tamoxifen
a
b
c
*
*
GFAP/DIG
B
CA1
10μm
NeuN/DIG
C
+Tamoxifen
a
b
c
GFAP/DIG
D
CA1
10μm
NeuN/DIG

Figure 3